Abstract

Bacteria associated with mammals are a rich source of microbial biodiversity; however, little is known concerning the abilities of these microbes to generate secondary metabolites. This report focuses on a bacterium isolated from the ear of a feral hog from southwestern Oklahoma, USA. The bacterium was identified as a new strain (PE36) of Brevibacillus latersporus, which was shown via genomic analysis to contain a large number of gene clusters presumably involved in secondary metabolite biosynthesis. A scale-up culture of B. latersporus PE36 yielded three bioactive compounds that inhibited the growth of methicillin-resistant Staphylococcus aureus (basiliskamides A and B and 12-methyltetradecanoic acid). Further studies of the isolate's secondary metabolome provided both new (auripyrazine) and previously-described pyrazine-containing compounds. In addition, a new peptidic natural product (auriporcine) was purified that was determined to be composed of a polyketide unit, two L-proline residues, two D-leucine residues, one L-leucine residue, and a reduced L-phenylalanine (L-phenylalanol). An examination of the genome revealed two gene clusters that are likely responsible for generating the basiliskamides and auriporcine. These combined genomic and chemical studies confirm that new and unusual secondary metabolites can be obtained from the bacterial associates of wild mammals.

Highlights

  • Nature has served as a valuable source of bioactive compounds with many natural products having entered into clinical use [1]

  • Bacteria associated with other microorganisms, plants, nematodes, insects and sponges produce an intriguing variety of secondary metabolites [9,10]; relatively little is known about the natural products generated by the microbes associated with wild mammals

  • The samples were spread onto agarbased media and over 160 bacterial colonies were streaked onto fresh plates

Read more

Summary

Introduction

Nature has served as a valuable source of bioactive compounds with many natural products (secondary metabolites) having entered into clinical use [1]. The natural product biosynthetic potential of this isolate was revealed using a combination of LC-MS, bioassays, and genomic data. The genome of B. laterosporus strain PE36 was evaluated in the secondary metabolite analysis pipeline antiSMASH [18] revealing 32 possible biosynthetic gene clusters.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.